In the latest session, Legend Biotech Corporation (NASDAQ: LEGN) closed at $66.54 down -3.51% from its previous closing price of $68.96. In other words, the price has decreased by -$2.42 from its previous closing price. On the day, 548796 shares were traded. LEGN stock price reached its highest trading level at $68.81 during the session, while it also had its lowest trading level at $66.32.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
For a deeper understanding of Legend Biotech Corporation’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.47.
Upgrades & Downgrades
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 12.04B and an Enterprise Value of 11.30B. For the stock, the TTM Price-to-Sale (P/S) ratio is 108.60 while its Price-to-Book (P/B) ratio in mrq is 16.85. Its current Enterprise Value per Revenue stands at 109.35 whereas that against EBITDA is -22.12.
Stock Price History:
Over the past 52 weeks, LEGN has reached a high of $73.30, while it has fallen to a 52-week low of $37.30. The 50-Day Moving Average of the stock is 58.33, while the 200-Day Moving Average is calculated to be 50.37.
For the past three months, LEGN has traded an average of 803.03K shares per day and 517.6k over the past ten days. A total of 170.54M shares are outstanding, with a floating share count of 168.20M. Insiders hold about 1.42% of the company’s shares, while institutions hold 38.80% stake in the company. Shares short for LEGN as of Apr 27, 2023 were 4.12M with a Short Ratio of 4.12M, compared to 5.9M on Mar 30, 2023.
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.8 for the current quarter, with a high estimate of -$0.48 and a low estimate of -$1.13, while EPS last year was -$0.3. The consensus estimate for the next quarter is -$0.82, with high estimates of -$0.48 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$1.66 and -$4.77 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$2.79, with 5 analysts recommending between -$0.99 and -$5.76.
A total of 8 analysts believe the company’s revenue will be $50.73M this quarter.It ranges from a high estimate of $91.4M to a low estimate of $37.8M. As of the current estimate, Legend Biotech Corporation’s year-ago sales were $11.97M, an estimated increase of 323.80% from the year-ago figure.
A total of 13 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $320.4M, while the lowest revenue estimate was $175M, resulting in an average revenue estimate of $239.35M. In the same quarter a year ago, actual revenue was $117M, up 104.60% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $524.89M in the next fiscal year. The high estimate is $839M and the low estimate is $357.8M. The average revenue growth estimate for next year is up 119.30% from the average revenue estimate for this year.